Elrazi Ali

ORCID: 0000-0002-8967-433X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Eosinophilic Disorders and Syndromes
  • Hemoglobinopathies and Related Disorders
  • Blood groups and transfusion
  • Chronic Lymphocytic Leukemia Research
  • Platelet Disorders and Treatments
  • Acute Myeloid Leukemia Research
  • COVID-19 Clinical Research Studies
  • Lymphoma Diagnosis and Treatment
  • Kruppel-like factors research
  • Acute Lymphoblastic Leukemia research
  • Heparin-Induced Thrombocytopenia and Thrombosis
  • Lung Cancer Research Studies
  • Iron Metabolism and Disorders
  • Cancer Immunotherapy and Biomarkers
  • Hepatitis C virus research
  • Blood Pressure and Hypertension Studies
  • Streptococcal Infections and Treatments
  • Autoimmune Bullous Skin Diseases
  • Venous Thromboembolism Diagnosis and Management
  • Dermatological and COVID-19 studies
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Amoebic Infections and Treatments
  • Blood disorders and treatments

Interfaith Medical Center
2022-2024

Hamad Medical Corporation
2020-2024

Saint Michael's Medical Center
2024

Hamad General Hospital
2020-2023

National Center for Cancer Care and Research
2021-2023

Jordan University of Science and Technology
2022

Weatherford College
2021

Qatar National Library
2021

University of Khartoum
2016-2020

Western University
2017-2018

Euglycemic diabetic ketoacidosis (EuDKA) secondary to Sodium-glucose co-transporter-2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2D) is a rare but increasingly reported phenomenon. Not much known about the burden of EuDKA patients on SGLT2i or associated factors. This retrospective cohort study tries delineate differences factors with development as compared hyperglycemic DKA. We conducted multicentre, across three tertiary care centers under Weill Cornell affiliated-Hamad Medical...

10.1038/s41598-021-89752-w article EN cc-by Scientific Reports 2021-05-13

Hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) patients has transitioned from the standard of care to a treatment option limited those with unsatisfactory tyrosine kinase inhibitor (TKI) responses and advanced disease stages. In recent years, threshold undergoing HSCT increased. Most CML now have life expectancies comparable general population, therefore, goal therapy is shifting toward achieving treatment-free remission (TFR). While TKI discontinuation...

10.3390/cancers16040754 article EN Cancers 2024-02-12

Eosinophils can be considered as multifunctional leukocytes that contribute to various physiological and pathological processes depending on their location activation status. There are emerging eosinophil-related considerations concerning COVID-19. Variable eosinophil counts have been reported during Whether these changes related the primary disease process or due immunomodulation induced by treatment has not yet elucidated.To describe in differential leukocyte including eosinophils, a...

10.23750/abm.v91i4.10564 article EN PubMed 2020-11-10

IgA nephropathy (IgAN) is the most frequent type of primary glomerulonephritis since first was described more than four decades ago. It prevalent cause glomerular disease that causes end-stage renal disease. In patients with IgAN, hematuria common reported symptom, particularly in those a preceding upper respiratory tract infection. Although pathogenesis IgAN usually multifactorial, autoimmune complex formation and inflammatory processes are widely recognized pathogenic mechanisms. Multiple...

10.1097/md.0000000000031219 article EN cc-by-nc Medicine 2022-12-02

Chronic myeloid leukemia (CML), while traditionally a disease of the elderly, has recently risen in incidence among younger patients. Hence, fertility concerns have emerged considering process and treatments, especially with current scarce conflicting recommendations. This review explores impact CML treatments including first-line tyrosine kinase inhibitors (TKIs) other on male chronic (CML) The aim this was to compile available evidence ultimately tailor treatment plans for patients whom...

10.3390/cancers16040791 article EN Cancers 2024-02-15

BACKGROUND Coronavirus disease 2019 (COVID-19) is a newly emerging that still not fully characterized. It caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), novel virus can be transmitted easily from human to mainly the route. Currently, there no specific treatment for COVID-19 or vaccine prevention. The has various degrees of severity. often presents with nonspecific symptoms such as fever, headache, and fatigue, accompanied (e.g., cough dyspnea) other systemic...

10.12659/ajcr.925932 article EN American Journal of Case Reports 2020-09-03

Multiple studies have demonstrated that tyrosine kinase inhibitors (TKIs) exert a significant extent of control over chronic myeloid leukemia (CML), as evidenced by such the population-based Swedish CML registry, which found patients reaching age 70 had relative survival rate close to one when compared general population. Consequently, new perspectives on safety treatments emerged, particularly in context their impact fatherhood men. According authors, this is first study examine effect TKIs...

10.7759/cureus.33407 article EN Cureus 2023-01-05

Abstract Severe COVID‐19 infection is associated with significant stress and marked immune response that can affect many organs precipitate DKA, pancreatitis, acute renal injury, which might be permanent.

10.1002/ccr3.3731 article EN cc-by Clinical Case Reports 2021-01-07

Abstract Guttate psoriasis is a rare dermatological presentation of SARS‐CoV‐2 infection and seen mainly in patients with an underlying disease psoriasis.

10.1002/ccr3.4568 article EN cc-by Clinical Case Reports 2021-07-01

BACKGROUND COVID-19 is a newly emerging disease that not yet fully understood. It caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), novel virus easily transmitted from human to through the route. Usually, it presents with fever, headache, fatigue accompanied symptoms like cough and dyspnea, other systemic involvements. Chronic lymphocytic leukemia (CLL) common lymphoproliferative neoplasm characterized absolute lymphocytosis demonstration of clonality unlike causes...

10.12659/ajcr.926062 article EN American Journal of Case Reports 2020-10-24

Coronavirus disease 2019 (COVID-19) is a recently discovered that has yet to be thoroughly described. It caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), novel virus can transmitted easily from human human, mainly the route. The often presents with non-specific symptoms such as fever, headache, and fatigue, accompanied (e.g., cough dyspnea) other systemic involvement. Currently, vaccination primary strategy prevent transmission reduce severity. However, vaccines have...

10.1016/j.amsu.2021.103164 article EN Annals of Medicine and Surgery 2021-12-06

<b><i>Introduction:</i></b> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the viral agent responsible for disease of 2019. The primarily a illness; however, multisystem involvement not uncommon. infection reported to be more severe in patients with multiple comorbidities and immunocompromised patients. Patients hematological malignancies are prone develop SARS-CoV-2 infection. had developed several mutations that resulted different strains virulence...

10.1159/000525750 article EN cc-by-nc Oncology 2022-01-01

<ns3:p>Background: The association between the haematological profile (including abnormal platelets) and malaria is not completely understood. There are few published data on profiles of patients in areas with unstable transmission. current study was conducted to investigate if parameters, including platelet indices, were reliable predictors for microscopically-diagnosed infection.</ns3:p><ns3:p> Methods: A case-control a total 324 participants (162 each arm) at out-patient clinic New Halfa...

10.12688/f1000research.11767.1 preprint EN cc-by F1000Research 2017-06-12

Priapism is a rare presentation and complication of ET that might be underreported. In ET, priapism can present as an ischemic or stuttering type. These patients are more likely to anemic have high platelet count.

10.1002/ccr3.3541 article EN cc-by Clinical Case Reports 2020-11-18

Olaparib is (ADP-ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to death cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by FDA in 2023 for treating castrate-resistant prostate (CRPC), there have been some reports myelodysplastic syndrome (MDS) and acute leukemia linked PARP use ovarian, breast, pancreatic breast cancers, no aplastic anemia after receiving PARPi therapy. case report...

10.1016/j.lrr.2024.100473 article EN cc-by Leukemia Research Reports 2024-01-01

Immune thrombocytopenic purpura (ITP) is a blood disorder in which antibodies coating platelets cause destruction the spleen with resultant low count and an increased tendency for bleeding. Coronavirus disease 2019 (COVID-19) illness caused by SARS-COV2; it was first identified December/2019; though mainly affects respiratory system, multisystemic complications are identified. Several ITP cases post mRNA SARS-CoV-2 vaccines were reported, different pathophysiology theories about underlying...

10.1016/j.idcr.2021.e01344 article EN cc-by IDCases 2021-01-01

Background and aims Coronavirus disease 2019 (COVID-19) is caused by a virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first pandemic wave, SARS-CoV-2 had developed significant changes mutations that resulted in emergence of different strains. Each strain varies its virulence severity. Most reports have shown Omicron variant causes mild illness. Little about impact patients with chronic myeloid leukemia. We present leukemia who infection their outcomes....

10.7759/cureus.23863 article EN Cureus 2022-04-05

Nivolumab is a humanized monoclonal anti-programmed cell death receptor-1 (PD-1) antibody that has been authorized for use in the treatment of advanced malignancies. Cutaneous reactions are most common immune-related adverse events reported with anti-PD-1 agents, and they range broadly from mild localized to rarely severe or life-threatening systemic dermatoses. The occurrence Steven-Johnson syndrome (SJS) toxic epidermal necrolysis (TEN) nivolumab an exceedingly rare phenomenon was only...

10.14740/jmc3992 article EN Journal of Medical Cases 2022-09-01

An 11-month-old full-term female infant was referred to the hematology clinic due marked anemia and neutropenia. She almost exclusively breastfed rejecting all trials for supplementary food including artificial formulas. Bone marrow aspirate revealed cytoplasmic vacuolization in precursors of myeloid erythroid series with significant dysgranulopoiesis dyserythropoiesis ringed sideroblasts. Flow cytometry analysis increased hematogones aberrant loss/downregulation CD33 on granulocytes...

10.1159/000505483 article EN cc-by-nc Case Reports in Oncology 2020-02-04
Coming Soon ...